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Titin exhibits an interaction between its PEVK segment and the actin ﬁlament resulting in viscosity, a speed dependent resistive
force, which signiﬁcantly inﬂuences diastolic ﬁlling in mice. While diastolic disease is clinically pervasive, humans express a
more compliant titin (N2BA:N2B ratio ∼0.5–1.0) than mice (N2BA:N2B ratio ∼0.2). To examine PEVK-actin based viscosity in
compliant titin-tissues, we used pig cardiac tissue that expresses titin isoforms similar to that in humans. Stretch-hold experiments
were performed at speeds from 0.1 to 10 lengths/s from slack sarcomere lengths (SL) to SL of 2.15μm. Viscosity was calculated
from the slope of stress-relaxation vs stretch speed. Recombinant PEVK was added to compete oﬀ native interactions and this
found to reduce the slope by 35%, suggesting that PEVK-actin interactions are a strong contributor of viscosity. Frequency sweeps
were performed at frequencies of 0.1–400 Hz and recombinant protein reduced viscous moduli by 40% at 2.15 μm and by 50%
at 2.25 μm, suggesting a SL-dependent nature of viscosity that might prevent SL “overshoot” at long diastolic SLs. This study is
the ﬁrst to show that viscosity is present at physiologic speeds in the pig and supports the physiologic relevance of PEVK-actin
interactions in humans in both health and disease.
1.Introduction
Diastolic (dys)function is of major clinical importance
and is characterized by both elastic [1–4] and viscous
properties [5–7]. The giant elastic protein titin (also known
as connectin [8, 9]) is well known to be related to the
elasticity of cardiac muscle impacting the end diastolic
pressure volume relationship (for current reviews see [10–
12]). These elastic properties arise from the three extensible
segments localized in the I-band of the sarcomere: the
tandem Ig segments, the proline-glutamic acid-lysine-valine
rich PEVK element, and the N2B unique sequence. Viscosity
is a speed-dependent resistive property of all biological
tissues [13]. Viscosity in cardiac tissues impacts diastolic
ﬁlling by slowing ventricular pressure relaxation and causing
a delayed relaxation phenotype during early ﬁlling [2, 5, 6].
The Ig domains that make up the tandem Ig segments
of titin’s spring region are a possible intrinsic source of
viscosity. Individual Ig domains were originally thought to
unfold during stretch and refold during release causing
a viscosity [14, 15], but single molecule and simulation
studies suggest that the domain unfolding is unlikely to
be a prominent process under physiologic conditions [16–
20]. Interactions between elements of the extensible I-band
of titin and other structures in the sarcomere are another
possible source of viscosity. The interaction between titin
and actin was hypothesized due to evidence of a viscoelastic
interaction in the sarcomere [21], close proximity of the
two ﬁlament types, and in vitro evidence of titin binding
to actin [22–25]. Yamasaki et al. ﬁrst demonstrated by
cosedimentation assays that the PEVK region, but not the
N2B element or Ig domains, interacted with actin [13];2 Journal of Biomedicine and Biotechnology
Kulke et al.’s F-actin cosedimentation assays supported this
ﬁnding [26]. Both studies showed that F-actin sliding in
the in vitro motility assays was slowed by the addition of
recombinantPEVKproteintotheassaybuﬀersuggestivethat
the PEVK adds a viscous force that slows ﬁlament sliding.
Mechanically, Yamasaki found a reduction in the stress-
response of rat cardiac myoﬁbers using exogenously added
recombinant PEVK proteins [13]. Kulke utilized gelsolin
extraction of thin ﬁlaments to abolish native actin-PEVK
interaction in myoﬁbrils and found that this reduced viscous
stress relaxation [26] (although such extraction potentially
releases near-Z-disk titin that is normally ﬁrmly bound to
actin [27]). Both studies conﬁrmed in the ﬁber/ﬁbril that a
viscous response was due to PEVK-actin interactions. The
development of a PEVK KO mouse model [28]p r o v i d e d
a new tool to study PEVK-actin interactions and its eﬀect
on viscosity. Utilizing skinned cells and ﬁbers from this KO
mouse, a 50% reduction was found in the viscosity in stress-
relaxation and viscous moduli in sinusoidal experiments
using protocols identical to the ones used in this study
[29]. Recently, using a PEVK KO mouse, we quantiﬁed the
contribution of PEVK-actin interactions to viscosity in an
ex vivo and in vivo whole heart preparation, and we showed
a key physiologic consequence that PEVK-actin interactions
control 30% of viscosity during early rapid ﬁlling [29].
Cardiac muscle of large mammals, including human,
coexpressesboththestiﬀerN2Bisoformandmorecompliant
N2BA isoform unlike that of small rodents that is dominated
by expression of the N2B cardiac isoform [10, 12]. The
PEVK element of the N2B isoform contains 7 exons with 5
PPAK (proline-rich) motifs that are negatively charged and
involved in actin binding [28, 30]. The PEVK region of the
cardiac N2BA isoform contains all of the elements expressed
in the N2B isoform and additional PEVK exons, including
additional PPAK repeats as well as two PolyE (glutamic acid
rich) motifs [30]. The PolyE motifs appear to have a stronger
binding aﬃnity to actin than the PPAK motifs [31]. Because
of these changes in PEVK expression and the expression of
additional Ig domains in N2BA dominant tissues [12], direct
extrapolations from the ﬁndings in small animals to humans
are diﬃcult. Thus, while characterization of the PEVK-actin
interaction shows physiologic relevance in small animals,
actual application in large mammals including humans
remains unclear. To study viscosity in tissues containing a
high N2BA:N2B ratio, we utilized tissues from the pig.
Viscous properties were probed using both stretch hold
and frequency sweep perturbations to quantify viscosity and
we utilized a competition assay with recombinant PEVK
proteins to disrupt the native PEVK-actin interactions.
2. Methods
2.1. Porcine-Skinned Fiber Preparation and Mechanics.
Porcine LV tissue was obtained as previously described [32].
Animal experiments were approved by the University of
Arizona Institutional Animal Care and Use Committee and
followed NIH guidelines for “Using Animals in Intramural
Research.” Brieﬂy, the heart was rapidly obtained from the
pig <5 minutes after sacriﬁce, washed with a calcium-free
HEPES-buﬀered solution ([in mM] 10HEPES; 133.5NaCl,
5K Cl, 1.2N aH 2PO4;1 . 2 M g S O 4, 11glucose, 4Na-Pyruvate
with 2.5U/L insulin, pH 7.44), dissected into small strips,
and placed in a skinning solution composed of relaxing solu-
tion ([in mM]: 10BES, 10EGTA, 6.56MgCl2, 5.88Na-ATP,
1DTT, 46.35potassium-propionate, 15creatine phosphate)
with 1% Triton X-100 (Thermo Scientiﬁc, Waltham, Mass)
and a high concentration of protease inhibitors ([in mM]
0.1E64, 0.4Leupeptin and 0.5PMSF) for 24–48hrs at 4◦C.
After skinning, tissues were washed with Triton-free relaxing
solution with protease inhibitors then inﬁltrated with a
50% (vol/vol) solution of relaxing solution and glycerol
at 4◦C then stored at −20◦C. Small ﬁbers were dissected,
glued to aluminum clips, and attached at either end to a
force transducer (AE801, SensorOne, Sausalito, Calif) and
length motor (308B, Aurora Scientiﬁc, Aurora ON, Canada)
and washed with relaxing solution with inhibitors. Cross-
sectional area (CSA) was measured (0.023 ± 0.002mm2).
All ﬁbers activated at 2.0μm sarcomere lengths (SL) using a
pCa 4.0 solution to conﬁrm ﬁber quality, achieving tensions
of 39.5 ± 2.5mN/mm2. Length perturbations and force
measurements were performed using a custom LabVIEW
interface (National Instruments, Austin, Tex)
Cardiac muscle ﬁbers were stretched with two length
perturbations to evaluate viscosity [29]. The ﬁbers were
stretched using a stretch-hold-release protocol from their
slacksarcomerelengthtoaSLof2.15μmat3speeds:0.1,1.0,
and 10.0lengths/s. After stretch, the ﬁbers were held at their
stretched length for 90 seconds, followed by a symmetric
release. A sinusoidal frequency sweep was applied at the end
of hold of the 0.1 length/s stretch with frequencies from 0.1
to 400Hz at an amplitude of +/−2% of the ﬁber length.
10 minutes of recovery time in between stretches was used.
In order to probe the dependence on sarcomeric strain,
frequency sweeps were also imparted at a SL of 2.25μm
(ﬁbers were stretched from slack to a SL of 2.25μma t
0.1lengths/sec).
To test the magnitude of PEVK-actin interactions,
recombinant PEVK fragments were expressed in E. coli
and puriﬁed as previously described [32]. Brieﬂy, cDNA
f r a g m e n t sw e r ea m p l i ﬁ e df r o mh u m a nc D N Aw i t hp r i m e r
pairs corresponding to the human cardiac I27-PEVK-I84
fragment with the ﬂanking Ig domains included to enhance
the stability of the protein. Ampliﬁed cDNA fragments
were inserted into a pETM11 vector, expressed in E.
coli, and the obtained fragments were sequence veriﬁed.
Fragments were puriﬁed then dialyzed into PBS ([in mM]
2.7KCl,1.5KH2PO4, 137 NaCl, 8 Na2PO4)and10%glycerol,
aliquoted, ﬂash frozen, and stored at −80◦C. For use,
proteins were thawed and dialyzed in relaxing solution with
protein inhibitors. PEVK fragments were added to the pig
ﬁbers to a ﬁnal concentration of 22μM in relaxing solution
with protease inhibitors, allowed to incubate for >1hr ,and
probed with the mechanical protocol described above.
2.2.AnalysisofSkinnedMuscleMechanics. Datawasanalyzed
oﬄine in a custom LabVIEW VI. Stress was calculated by
dividing measured force by cross-sectional area. For stretch-
hold experiments, stress was measured at the end of theJournal of Biomedicine and Biotechnology 3
stretch to calculate the peak stress and again at the end
of the hold (90sec after peak) to calculate a steady state
stress. Analysis methodology was adapted from previous
work [33, 34]. The viscous stress is calculated as the peak
minus steady-state stress during the hold. The viscosity was
calculated as the slope between the viscous stress and the
log10 of the stretch speed (in lengths/s).
Frequency sweep data was analyzed to obtain viscous
moduli [35]. The stress was used to ﬁrst calculate the
complex stiﬀnessasthestressdividedbytheamplitudeofthe
imposed length change (normalized to ﬁber length). Phase
delaywascalculatedasthephasediﬀerencebetweenthestress
and strain signals. The viscous modulus was then calculated
ascomplexstiﬀnesstimesthesineofthephasedelay[35](see
inset of Figure 3(a)) at all frequencies.
2.3. Statistics. Data analysis was performed in MS Excel.
Student t-test was used to compare the viscosity (slope and
viscous modulus at a given frequency) between groups. A P
value < 0.05 was considered signiﬁcant.
3. Results
Using titin protein gels, we ﬁrst established the titin isoform
expression ratio of porcine cardiac LV tissues and found
that the N2BA:N2B isoform ratio is ∼1.0 (Figures 1(a)
and 1(b)). This expression ratio is much higher than that
of the mouse LV (∼0.2) and is slightly higher than that
of normal human LV and similar to that of human LV
of DCM patients (Figure 1(b)). To quantify viscosity, we
stretched skinned pig LV muscle from their slack SL (∼
1.9μm) to 2.15μm and then held length constant for 90
sec to observe stress relaxation, followed by a release back
to the slack length. Figure 1(c) shows two examples of
such stretch-hold-release experiments, one carried out in
relaxing solution (Ctrl) and the other in relaxing solution
to which exogenous PEVK had been added (we conﬁrmed
the purity of the expressed PEVK using gels, see inset of
Figure 1(c)). We measured viscous stress (σv) from the stress
relaxation during the hold phase of the protocol (explained
at top of Figure 2(a)). Viscous stress was measured at three
stretch speeds encompassing subphysiologic (0.1lengths/s)
to supraphysiologic speeds (10lengths/s) and the magnitude
of the stress relaxation, deﬁned by the peak minus steady-
statestress(Figure 2(a),inset),wasdeterminedateachspeed.
Viscosity was quantiﬁed as the slope of stress relaxation
versus (log) speed. At SL of 2.15μm, the viscosity (slope)
was reduced by 35%(P = 0.03) when ﬁbers were incubated
withrecombinantPEVK(Figure 2(b)).Theseresultsindicate
that PEVK-actin interactions are present and relevant in
tissues expressing high levels of the compliant titin N2BA
isoform.
We also measured the viscous moduli during a sinusoidal
oscillation protocol at frequencies from 0.1 to 400Hz and
usinganamplitudeof2%oftheﬁberlengthandrepeatedthe
protocol in the absence and presence of recombinant PEVK.
Frequency analysis provides a robust method to quantify
the viscous response of a tissue at a wide array of speeds
[29, 35]. To quantify the modulus, the ratio of the stress
response and length perturbation was ﬁrst used to calculate
a complex stiﬀness and the phase delay between stress and
length is used to calculate the viscous modulus (Figure 3(a)).
The viscous modulus was reduced by 40% by the treatment
with recombinant PEVK at SL of 2.15μm( Figure 3(b)).
We also performed experiments at a SL of 2.25μma n d
found that the viscous moduli were reduced by 50% at all
frequencies (Figure 3(c)). Importantly, the viscous modulus
maintained a constant reduction at physiologic frequencies
(∼0.5–2 Hz corresponding to the heart rate in the pig) for
both SL ranges. These data indicate that the introduction of
recombinant PEVK does reduce the viscosity of the system
at all frequencies, including frequencies corresponding to
physiologic heart rates, and reveals that it does this in a SL-
dependent manner.
4. Discussion
In resisting the rapid expansion of the left ventricle, viscosity
is an important modulator of diastolic function [2, 5–7].
While previous work has shown a contribution of PEVK-
actin interactions to viscosity both in vitro [13, 26, 36,
37] and in vivo [29], such ﬁndings were largely obtained
in small rodents that express titin that is stiﬀer than in
larger mammals and often at speeds below [13, 36]o r
above [26] physiologic rates. Yet the relevance to human
cardiac function and dysfunction is not direct, owing to the
increased expression of the compliant N2BA isoform that
contains additional Ig domains and a longer PEVK domain.
To determine the viscous properties of titin in a large animal
model with a human-like titin isoform expression ratio, we
investigated pig myocardial tissues. Additionally, we utilized
recombinant PEVK proteins to interrupt native PEVK-actin
interactions.
PEVK-actin interactions in the pig were signiﬁcantly
reduced by competitive binding of recombinant PEVK to the
actin ﬁlament. This reduced the viscous response to stretch
by 35% and the viscous moduli by more than 40% at a SL
of 2.15μm (Figures 2 and 3). At longer sarcomere lengths
(2.25μm) that are likely to be reached during diastole in
pigs [38], the viscous moduli obtained with the sinusoidal
analysis increased to ∼50%. Thus, PEVK-actin interaction
is a major source of viscosity in large mammals like the
pig. These novel ﬁndings are the ﬁrst to quantify viscosity
across physiologic speeds in tissues expressing high levels of
compliant N2BA isoforms.
Our ﬁndings indicate that PEVK-actin interaction is
likely to be physiologically important in humans where
viscosity inﬂuences relaxation [2, 5, 6]. The characterization
ofdelayedrelaxation[39]haslongbeenaclinicalindicatorof
diastolic dysfunction in echocardiography. Recent advances
in modeling further support that the delayed relaxation
phenotype is caused by a viscous force [2]. Recently, we
used transmitral Doppler echocardiography in a KO mouse
deﬁcient in PEVK and found a signiﬁcant reduction in
viscosity during early rapid ﬁlling [29]. The ability to
translate the echocardiographic ﬁndings in mice to humans
could not be fully appreciated until the present results on4 Journal of Biomedicine and Biotechnology
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Figure 1: Porcine myocardial characteristics. (a) Pig LV tissues electrophoresed on a large pore 1% agarose gel indicate a nearly 1:1
N2BA:N2B ratio. (b) N2BA/N2B ratios range from 0.2 in small animals to 1.0 in human dilated cardiomyopathy (DCM). (c) Example
mechanical perturbation of pig tissue from slack SL to 2.15μm at 10.0lengths/s in control conditions and incubated with recombinant
PEVK protein to inhibit native PEVK-actin interactions showing reduced stress relaxation (arrows). Inset: SDS-PAGE indicating the high
purity of the recombinant PEVK protein fraction that was used. See text for details.
pig myocardium that showed a clear presence of viscosity in
tissues with a high N2BA:N2B ratio. Our work establishes
that despite the longer PEVK element and distinct sequence
composition of the N2BA PEVK, PEVK-actin interactions
are present in myocardial tissues with human-like titin
isoformexpression.Thus,thisinteractionisconservedacross
species, supporting the importance of these interactions to
diastolic function.
The SL-dependence of the viscous modulus (Figure 3)
was unexpected and may indicate that at longer SL where the
PEVK is stretched to a higher degree additional binding site
for actin are available than at short SL or, alternatively, that
the lattice compression that occurs at long SL enhances the
interaction [29]. The increased viscosity at longer SL might
reduce any potential SL “overshoot” during ﬁlling [36, 40]
and may allow for more precise end-diastolic SL control.Journal of Biomedicine and Biotechnology 5
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Figure 2: Measurement of viscosity from stress relaxation data in pig tissue. (a) Example viscosity data derived from stress relaxation in
a ﬁber untreated (CTRL, black) and in presence of recombinant PEVK protein (+PEVK, gray). Inset: schematic of explaining how viscous
stress (σv) was determined. (b) Exogenously added PEVK reduces the viscosity (slope) by 35%. See text for details.
The competition assays with recombinant PEVK reduced
viscosity by only 40–50%. This incomplete inhibition is
possibly due to the inability of the added PEVK to com-
pete oﬀ all native PEVK-actin interactions. Alternatively,
it indicates that there is an additional source of viscosity,
a possibility that is consistent with results of the PEVK
KO mouse model that also show that in absence of
the PEVK element myocardial tissue continues to display
∼50% of the viscosity found in wildtype myocardium [29].
Stretch-hold and frequency sweep protocols in myoﬁlament
extracted mouse ﬁbers have negligible viscosity suggesting
that the extracellular matrix contributes little to viscosity
of the myocardium [29]. Thus, the non-PEVK source of
viscosity is likely to arise from interactions that involve
the myoﬁlaments. In our studies, in PEVK KO mice, we
evaluated microtubules, a known source of viscosity under
pathological conditions [34, 41, 42]. However, colchicine
treatment produced no eﬀect on viscosity of the intact heart
neither in WT nor in PEVK KO mice [29], suggesting that,
in normal hearts, there is little contribution of microtubules
to viscosity. Thin-thick ﬁlament interaction is unlikely
because this predicts that viscosity would be increased
when the myoﬁlament lattice is compressed in PEVK KO
tissue and this is not what we observed in our previous
studies [29]. Possibilities that require future testing are
intermolecular interactions between adjacent titin molecules
and interactions between intermediate ﬁlaments and any
of the myoﬁlament types. In summary, although additional
sources of viscosity are likely to exist, the PEVK-actin
interaction is the only well-established molecular source
of viscosity in cardiac tissues and contributes up to half
of the total viscosity of skinned myocardium in relaxing
solution.
It has previously been shown that PEVK-actin inter-
action can be regulated by S100A1, a calcium binding
protein present in cardiac tissues (for recent review see
[43]). S100A1 is a member of the S100 calcium binding
proteins that is preferentially found in cardiac tissues.
S100A1 normally targets to calcium handling proteins (the
sarcoplasmic reticulum, RyR2), but also localizes in the I-
band of the sarcomere [13]. When present in the sarcomere
and activated by the presence of physiological calcium levels,
S100A1 inhibits PEVK-actin interactions [13, 36]. Thus,
PEVK-actin interaction-based viscosity can be turned oﬀ
during systole when high calcium levels are present in the
cytosol and turned on again during diastole when calcium
levels fall. A second mechanism shown to inﬂuence PEVK-
actin interactions is protein kinase C-alpha (PKCα) phos-
phorylation of titin. PKCα phosphorylation occurs at two
sites in the PEVK element that are conserved across a large
numberofmammalianspeciesincludingthemouse,pig,and
human [32]. In both pig and mouse skinned cardiac ﬁbers
[32, 44], PKCα treatment increased viscosity by 20–30% at
physiologic speeds; the eﬀect was ampliﬁed by pretreating6 Journal of Biomedicine and Biotechnology
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Figure 3: Measurement of viscous moduli via sinusoidal analysis in pig tissue. (a) The frequency sweep perturbation is imparted after a
90-second hold at SL of 2.15 or 2.25μm. The viscous modulus is calculated utilizing the magnitude of the stress response, magnitude of the
length perturbation and phase delay (schematic, right). (b) The viscous modulus measured in control tissues at SL of 2.15μm (CTRL, black)
is reduced in the presence of recombinant PEVK proteins (+PEVK, gray) by 40%. (c) At a SL of 2.25μm, adding PEVK protein (+PEVK,
gray) reduces the viscous modulus at all frequencies. ∗ indicates P<0.05 across the frequencies noted by the horizontal bar. See text for
details.
theﬁbersbyproteinphosphatase1(PP1)todephosphorylate
titin [32]. These changes in viscosity indicate a potentially
large dynamic range by which viscosity can be modulated.
The understanding of the functional eﬀects of PKCα phos-
phorylation and its regulation may aid in our understanding
of the underlying dysfunction, for example, in heart failure
where PKCα is upregulated [45, 46]. These factors provide
a potential path for clinical management of cardiac diastolic
dysfunction.
5. Conclusion
This study establishes the presence of PEVK-actin inter-
actions in a large mammal, the pig, and is the ﬁrst to
conclusively determine with physiological stretch protocols
the magnitude of PEVK-actin interactions in hearts with
a human-like titin isoform expression ratio. Competition
assays with exogenous recombinant protein show that the
magnitude of this contribution is up to 50% of the totalJournal of Biomedicine and Biotechnology 7
viscosity seen in these tissues. Furthermore, we found that
PEVK-based viscosity is larger at longer SL, a property that
mightaidinpreventingSLovershootattheendofﬁlling,and
because of the inﬂuence of PEVK-actin interactions on early
rapidﬁlling,modulationoftheseinteractionsareofpotential
clinical importance.
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